Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ad-CIITA
- Development stage
- Preclinical
- Lead developer
- German Cancer Research Center
- Modality
- Gene Therapies
- Administration
- Intratumoral, Intravenous
01
Overview
Ad-CIITA (also known as AdV-CIITA) is a replication-deficient serotype 5 adenoviral vector engineered to deliver the Class II Major Histocompatibility Complex (MHC-II) Transactivator (CIITA) gene. Developed as a cancer gene therapy, Ad-CIITA is designed to infect tumor cells, such as glioblastoma cells, and induce the expression of MHC-II molecules on their cell surface. This converts the tumor cells into surrogate antigen-presenting cells (APCs) capable of priming and activating CD4+ and CD8+ T cells, thereby overcoming the immunosuppressive tumor microenvironment and promoting anti-tumor immune responses.
- Other names
- Ad5-CIITAAd-5-CIITAAd 5-CIITAadenovirus-mediated MHC-II Transactivator CIITA gene therapyadenovirus-mediated delivery of the MHC-II Transactivator CIITA gene
02
Targets
CXADR (Coxsackievirus and adenovirus receptor)
Beyond the preview
Go deeper on Ad-CIITA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ad-CIITA.